141593-56-8

Basic information

• Product Name: 1-AZABICYCLO[3.2.1]OCTANE-5-CARBOXALDEHYDE
• Synonyms: 1-AZABICYCLO[3.2.1]OCTANE-5-CARBOXALDEHYDE
• CAS NO: 141593-56-8
• Molecular Formula: C8H13NO
• Molecular Weight: 0
• Mol File: 141593-56-8.mol

Chemical Properties

• Boiling Point: 199.7°C at 760 mmHg
• Flash Point: 67.8°C
• Appearance: /
• Density: 1.08g/cm³
• Vapor Pressure: 0.337mmHg at 25°C
• Refractive Index: 1.526
• CAS DataBase Reference: 1-AZABICYCLO[3.2.1]OCTANE-5-CARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-AZABICYCLO[3.2.1]OCTANE-5-CARBOXALDEHYDE(141593-56-8)
• EPA Substance Registry System: 1-AZABICYCLO[3.2.1]OCTANE-5-CARBOXALDEHYDE(141593-56-8)

Safety Data

• Hazardous Substances Data: 141593-56-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H13NO/c10-7-8-2-1-4-9(6-8)5-3-8/h7H,1-6H2

Upstream product

• 142483-35-0 N-methoxy-N-methyl-1-azabicyclo<3.2.1>octane-4-carboxamide 
• 148672-75-7 1-azabicyclo[3.2.1]octan-5-methanol 
• 119103-01-4 5-(chlorocarbonyl)1-azoniabicyclo[3.2.1]octane 
• 119103-00-3 5-carboxy-1-azoniabicyclo[3.2.1]octane 
• 119102-52-2 ethyl 1-azabicyclo[3.2.1]octane-5-carboxylate 

Downstream Products

• 142483-61-2 5-ethynyl-1-azabicyclo<3.2.1>octane 

Relevant articles and documents

NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity

Method of treating gastrointestinal motility disorders

The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.

Method of treating urinary bladder dysfunctions

The present invention relates to a novel method for treating a mammal suffering from urinary bladder dysfunctions.

Design of [R-(Z)]-(+)-α-(methoxyimino)-1-azabicyclo[2.2.2]octane-3- acetonitrile (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere

Loss of cholinergic function is believed to be implicated in the cognitive decline associated with senile dementia of the Alzheimer type (SDAT). The disease is characterized by progressive loss of muscarinic receptors located on nerve terminals while postsynaptic muscarinic M1 receptors appear to remain largely intact. Muscarinic agonists acting directly on postsynaptic receptors offer the prospect of countering the cholinergic deficit in SDAT. This study describes a novel series of azabicyclic muscarinic agonists, which incorporate an oxime ether or modified oxime ether group as an ester bioisotere. Modification of the oxime ether function by the introduction of electron withdrawing groups led to the finding that the (Z)-N-methoxy imidoyl nitrile group serves as a stable methyl ester bioisostere. This culminated in the discovery of the quinuclidinyl N-methoxy imidoyl nitrile (R)-(+)-(Z)-5g which is a functionally selective muscarinic M1 partial agonist currently in phase III clinical trials for the treatment of SDAT. The selective profile of R-(+)- (Z)-5g can be rationalized in terms of the relative affinity of the compound at muscarinic receptor subtypes, the degree of agonist efficacy, and brain penetrancy.

Heterocyclic compounds and their preparation and use

The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

Certain 3-(1,2,5-oxa- or thiadiazol-4-yl)-1-azabicyclo [2.2.2]octanes having pharmaceutical properties

The present invention relates to therapeutically active piperidine compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.

Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl- based muscarinic receptor ligands has been studied, and the exo- azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.